Information Provided By:
Fly News Breaks for February 20, 2020
Feb 20, 2020 | 16:16 EDT
Cantor Fitzgerald analyst Kristen Kluska initiated coverage of Celldex with an Overweight rating and $8 price target. Celldex has shown early, promising signals across monotherapy and combination studies in patients who have failed numerous other treatment approaches and has multiple "shots on goal" with its programs, the analyst tells investors.
News For CLDX From the Last 2 Days
There are no results for your query CLDX